FDA approves bemotrizinol sunscreen, Parsol Shield FDA approval marks first new UV filter in U.S. in more than 25 years
The U.S. Food and Drug Administration (FDA) has formally approved bemotrizinol (Parsol Shield) as a new OTC sunscreen active, designated GRASE for adults and children 6 months and older, permitting use in formulations up to 6% after safety and efficacy review.
- New active: FDA designates bemotrizinol as a GRASE active ingredient for OTC sunscreens at up to 6% — see the dermatology and regulatory review and an analysis of the proposal.
- Market timing: DSM will sell bemotrizinol in the U.S. as Parsol Shield, with products expected in stores in 2026 and an 18‑month exclusivity period for DSM’s licensees (AFS Law analysis).
- Regulatory path: The change came via the updated OTC Monograph Order Request (OMOR) process that lets companies petition for new monograph ingredients — more at the FDA Q&A on sunscreen monograph changes (FDA Q&A).
A regulatory milestone: first new U.S. UV filter in decades
The FDA’s amendment to Monograph M020 to add bemotrizinol (BEMT) as a Category 1, Generally Recognized As Safe and Effective (GRASE), sunscreen active is the first such addition in more than 25 years. For decades, the U.S. sunscreen monograph listed filters frozen in the late 1990s; recent OTC reform and the OMOR route created a path to modernize that list (dermatology/regulatory review; FDA Q&A).
Parsol Shield FDA approval and market timing
DSM Nutritional Products filed a Tier 1 OMOR requesting bemotrizinol’s addition. After reviewing human safety, pharmacokinetic and efficacy data, the FDA finalized the change to permit bemotrizinol in specified dosage forms — lotions, creams, sprays, sticks and more — at concentrations up to 6% (AFS Law; regulatory review).
Exclusivity: DSM will market bemotrizinol under the trade name Parsol Shield in the U.S., with an expected 18‑month exclusivity period before other manufacturers may use the ingredient under the monograph.
What bemotrizinol is and how it works
Bemotrizinol (BEMT) is an organic, broad‑spectrum UV filter widely used in Europe and Asia. It offers strong UVA and UVB protection, and is noted for high photostability, meaning it resists breakdown in sunlight better than some older chemical filters. Manufacturers use it both as a stand‑alone broad‑spectrum component and as a booster to improve overall formula performance (see review).
Safety, absorption and irritation: what the data show
The FDA’s GRASE determination relied on human clinical and pharmacokinetic studies showing low systemic absorption at 6% concentrations, plasma levels below the agency’s internal exposure thresholds, few and mostly mild adverse events, and low rates of skin irritation. International post‑marketing experience — including authorization at up to 10% in some regions and 6% in Canada — reinforced the safety dossier (dermatology/regulatory review).
How the OMOR process made this possible
The OTC Monograph Order Request (OMOR) pathway — introduced under recent OTC reform — allows companies to submit comprehensive modern safety, toxicology and efficacy data to request monograph changes. DSM used the OMOR route and the FDA reviewed the submission under updated standards, ultimately amending the sunscreen monograph to add bemotrizinol (regulatory review; AFS Law).
Comparison with older U.S. filters
Many U.S. sunscreens have relied on filters developed decades ago; some have raised concerns about photostability or systemic absorption in past reviews. Bemotrizinol’s advantages include broad UVA+UVB coverage, strong photostability, and good cosmetic compatibility — attributes that can help produce lighter, more cosmetically acceptable sunscreens that people are more likely to wear consistently (see review).
Official and expert voices
“The agency had moved too slowly in this space and Americans deserved timely access to safe, effective OTC products,” said FDA leadership in commentary accompanying the regulatory change; agency officials called bemotrizinol “a welcome addition” that brings U.S. sunscreen regulation closer to global standards (dermatology/regulatory review).
Public‑health context: sunscreen is one tool among many
FDA guidance: Sunscreen complements other sun‑safety measures. The agency recommends broad‑spectrum sunscreens SPF 15 or higher for daily protection, higher SPF for prolonged outdoor exposure, reapplication every two hours, and combining use with protective clothing, shade and timing strategies (FDA Q&A).
What to watch next
- Which U.S. brands adopt Parsol Shield first and in which product formats (facial, sprays, sport formulas).
- How labeling and marketing highlight bemotrizinol (e.g., “European‑grade” or “new generation” protection).
- Real‑world safety and tolerability data collected post‑launch, and additional OMOR filings for other filters (bisoctrizole, drometrizole trisiloxane).
Implications for Redding, California
Economic: Local retailers, pharmacies, outdoor outfitters and big‑box stores in Redding may begin stocking higher‑performing sunscreens in 2026; broader availability and competition could follow after DSM’s 18‑month exclusivity.
Political: The decision may be cited locally as evidence that regulatory reform can balance safety with faster market access.
Social and cultural: Redding’s outdoor lifestyle — fishing, agriculture, hiking, wildfire response — means improved sunscreen compliance could reduce sunburns among workers and families. Approval for children 6 months and older is especially relevant to parents.
Practical applications for residents
Look for products listing bemotrizinol or Parsol Shield on the Drug Facts active‑ingredients panel when products reach the U.S. market. Expect initial DSM licensee products in 2026, followed by broader choices after the exclusivity window. Continue core sun‑safety steps: use broad‑spectrum SPF 15+ (or higher for long outdoor periods), reapply every two hours, wear hats and protective clothing, and seek shade during peak sun times (FDA guidance).
